In honor of the 15-year anniversary of the founding of the Clinical Data Interchange Standards Consortium (CDISC) and the recently approved CDISC status as a 501(c)(3) charitable foundation, the Annual Report for year 2011 has been released and is available for download on the CDISC website.
In honor of the 15 year anniversary of the founding of the Clinical Data Interchange Standards Consortium (CDISC) and the recently approved CDISC status as a 501(c)(3) charitable foundation, the Annual Report for year 2011 has been released and is available for download on the CDISC website.
Key successes CDISC has had over the past 15 years are displayed graphically in a two-page timeline detailing major achievements since the organization’s founding in 1997. The report includes the mission and vision of CDISC, milestones for year 2011, and information about CDISC-certified education. Trends in CDISC membership and current leadership information are also detailed. Fascinating insight is given in the Annual Report to the rapid growth and productivity of CDISC since its beginnings as a strictly volunteer organization.
Readers also have the opportunity to get a closer look at where CDISC is heading over the next three years, through the inclusion of the CDISC Strategic Goals for 2012-15. The CDISC Board of Directors has been focused on delineating this new set of Strategic Goals since its Annual Meeting in 2011, and these were officially launched in January 2012. In summary, these five goals focus on: 1) supporting data aggregation and secondary use of research data; 2) enabling interoperability between clinical care and clinical research; 3) developing CDISC SHARE (shared health and research electronic library); 4) expediting the development of new therapeutic area standards to augment the CDISC foundational standards to support the needs of researchers and the FDA; and, 5) leveraging our global, nonprofit, vendor neutral, independent status to forge productive collaborations with and ensure value for key stakeholder communities.
“CDISC prides itself on doing its utmost to provide understandable, transparent information about the operational activities of the organization,” stated Dr. Rebecca Kush, CDISC President and CEO. “This first public Annual Report is a major accomplishment for CDISC, displaying the incredible effort and dedication of a multitude of members, volunteers and CDISC staff, who have worked around the world for 15 years to make CDISC what it is today-the common language for clinical research.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.